Two renowned research companies – one focused on preclinical research and discovery, the other on tailored microbiomic analysis – team up in order to help uncover the microbiomic components of diabetes, obesity and NAFLD/NASH
Hørsholm, August 29, 2016 – Gubra ApS and Clinical-Microbiomics A/S announced today a strategic partnership focusing on analyzing the role of the microbiome in conditions related to diabetes, obesity and NAFLD/NASH. The combined expertise and resources of these two world-leading research companies will enable a fast and customer tailored pre-clinical assessment of the impact of drugs and diet on the gut microbiome.
Gubra is a world leader in the field of pre-clinical research in the metabolic space and delivers scientific guidance and contract research services to a plethora of big pharma and biotech companies worldwide. Clinical-Microbiomics is a leading consulting firm in the microbiomics field providing tailored bioinformatics analyses and data integration. As a result of this collaboration, clients will benefit from unparalleled guidance and analysis covering the full spectrum of pre-clinical research, from choice of model and experiment design (in vivo pharmacology, histology, stereology, molecular biology, blood parameter assays etc.) to metagenomic profiling, bioinformatics and statistical analysis tailored to answer biomedical questions defined in collaboration with clients.
"This collaboration is a natural step for us at Gubra, as we experience increasing demand from clients with interests in the microbiome space", said Henrik Blou, Gubra CEO. "It was important for us to find a collaboration partner that shares our values with regards to scientific excellence and a client-centric approach. In Clinical-Microbiomics, we have found such a partner, and we are very happy that we can supplement our service portfolio with their expertise."
"Microbiome analysis is a complex field but in recent years we have seen tremendous advances that have opened our eyes for the potential of the microbiome in relation to development of novel therapeutics and food products," said Dr. Martin Santini, Clinical-Microbiomics CEO. "Together with Gubra, we have a compelling package for both pharma and biotech customers with pre-clinical stage programs."
About Gubra ApS
Gubra is a privately-held biotech company. Gubra's focus is diabetes, obesity and related metabolic disorders. Within these core areas, Gubra delivers preclinical in vivo, in vitro and histology services to their partners. In addition to the CRO services, Gubra has several active early target, biomarker and peptide discovery programs. For more information, visit www.gubra.dk.
About Clinical Microbiomics A/S
Clinical-Microbiomics is a client-centric contract research organization specialized in extracting key biological insights from microbiome metagenomics. Through development of tailor-made bioinformatics tools, Clinical-Microbiomics assists partners in pharma and biotech to answer specific biomedical questions and increase the success rate of their drug discovery and development projects. For more information, visit www.clinical-microbiomics.com.
For further information, please contact:
Henrik Blou, Gubra ApS: email@example.com, +45 3152 2650
Martin Santini, Clinical-Microbiomics A/S: firstname.lastname@example.org, +45 5388 1254